C
CorFlow Therapeutics
Biotech & Life Sciences · Baar, Switzerland · Founded 2016
The first combined diagnostic and therapeutic medical device for improving microvascular obstructions after a heart attack MoreLess
CorFlow Therapeutics AG is a Swiss-based medical device company that develops solutions for heart attack patients with microvascular obstruction (MVO). The company's flagship product is the CorFlow Controlled Flow Infusion System, a technology designed to diagnose and treat MVO in the catheterization laboratory.
CorFlow's business model revolves around the development and commercialization of its proprietary medical devices. The company targets cardiologists and healthcare institutions as its primary clients. By providing a novel approach to treating MVO, CorFlow aims to improve patient outcomes and reduce the economic burden of cardiovascular diseases. The company has secured significant funding from venture capital firms, which will be used to advance its clinical programs and prepare for market entry.
Keywords: medical devices, cardiovascular, microvascular obstruction, MVO, heart attack, cardiology, CorFlow Controlled Flow Infusion System, MOCA-II, cardiac care, diagnostics
Company overview
CorFlow Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- Baar, Switzerland
- Employees
- 37
- Open positions
- None listed
- Dealroom signal
- 91.6
Valuation & funding
CorFlow Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Sep 2024 | $48M | $194M | Wellington Partners · KOFA Healthcare Investments · Unorthodox ventures · Mérieux Equity Partners | ↗ |
| SERIES AOther financing | Mar 2021 | $7.3M | $29M | 415 Capital | ↗ |
| GRANTOther financing | Nov 2018 | $1.6M | — | Innosuisse | ↗ |
| SEEDOther financing | Sep 2018 | $4.4M | $18M | Undisclosed | ↗ |
| SEEDOther financing | Oct 2017 | $2.5M | $9.9M | Arshad Quadri · Dr. Jean-Claude Laborde | ↗ |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $450K | 0% | 37 |
| 2025 | $450K | 0% | 32 |
| 2024 | $450K | 0% | 20 |
| 2023 | $450K | 0% | — |
| 2022 | $450K | 0% | — |
| 2021 | $450K | 0% | — |
| 2020 | $450K | — | — |
Growth signals
CorFlow Therapeutics website traffic
Latest recorded traffic for CorFlow Therapeutics is 1.1K monthly website visits, up 1122.2% over the last three months. CorFlow Therapeutics's team grew 15.6% over the past year.
Comparisons
CorFlow Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
CorFlow Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
13 investors on CorFlow Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where CorFlow Therapeutics has talent and traffic
team presence
In the news
Latest news about CorFlow Therapeutics
Recent press, funding announcements, and product moves mentioning CorFlow Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about CorFlow Therapeutics
An AI-synthesized read of the highest-engagement posts about CorFlow Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CorFlow Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.